Vaccines Market Size and Growth 2031

Historic Data: 2021-2023   |   Base Year: 2024   |   Forecast Period: 2025-2031

Vaccines Market Size and Forecast (2021-2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: Type (Conjugated Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, and Toxoid Vaccines), Indication (HPV, PCV, DTP, Hepatitis, Influenza, Dengue, and Others), Route of Administration (Injection, Oral, and Other), Age Group (Pediatric and Adult), and Geography

  • Report Date : Jul 2025
  • Report Code : TIPRE00015468
  • Category : Life Sciences
  • Status : Published
  • Available Report Formats : pdf-format excel-format
  • No. of Pages : 150

The vaccines market size is projected to reach US$ 118.94 billion by 2031 from US$ 80.45 billion in 2024. The market is expected to register a CAGR of 5.7% during 2025–2031. Integration of artificial intelligence and big data in vaccine development is emerging as a significant trend in the vaccines market.

Vaccines Market Analysis

The vaccines market is witnessing substantial growth due to a surge in infectious diseases and heightened public awareness following the COVID‑19 pandemic. Immunization programs across the world have intensified to tackle the rising disease burden from influenza, HPV, and hepatitis. Technological innovation, notably the advent of mRNA, viral-vector, recombinant platforms, AI-driven antigen design, and advanced delivery systems, has accelerated R&D pipelines and enabled rapid, scalable development. Additionally, government funding and policy support play crucial roles: national immunization initiatives, accelerated regulatory pathways, and public–private partnerships such as Gavi and COVAX are lowering barriers and expanding access. Growing healthcare investment in emerging markets, especially Asia Pacific, where expanding middle classes and enhanced infrastructure are boosting uptake, further strengthens market prospects. These factors collectively contribute to the sustained expansion of the vaccines market.

Vaccines Market Overview

The global vaccines market is undergoing accelerated expansion, driven by the expanding burden of infectious diseases, such as influenza, HPV, COVID‑19, and emerging pathogens, emphasizing the urgent demand for preventive healthcare solutions. Key market drivers include cutting-edge innovations in vaccine technologies, notably mRNA, viral-vector, recombinant, and nanotechnology-based platforms, which significantly enhance development speed and efficacy. Additional factors fueling the market growth encompass increasing urbanization and population density, greater uptake of adult and elderly vaccination, use of combination vaccines that simplify immunization schedules. Furthermore, sustained investment in research and development targeting non-infectious diseases—such as cancer and allergies—is broadening the scope and impact of vaccines.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Vaccines Market: Strategic Insights

vaccines-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Vaccines Market Drivers and Opportunities

Surging Immunization Programs and Government Initiatives Bolster Market

Immunization programs offer services that ensure immunity to vaccine-preventable diseases. These services include documenting evidence of immunity, administering immunizations and re-immunizations, and maintaining records for reporting to state or local immunization information systems (IIS), also known as vaccine registries.

The Essential Programme for Immunization (EPI), developed by WHO in 1974, was designed to coordinate the targeted implementation of vaccination through national immunization programs. This initiative has been instrumental in expanding global vaccine access. Additionally, the establishment of Gavi, the Vaccine Alliance, an independent multilateral funding mechanism in 2000, aimed at increasing global access to vaccines, has played a critical role in facilitating vaccine introduction in low- and middle-income countries (LMICs). According to an article published in the Journal of Infectious Diseases in October 2021, it is estimated that vaccine access has prevented at least 37 million deaths in 98 LMICs by protecting against 10 vaccine-preventable diseases, including Haemophilus influenzae type B, Japanese encephalitis, Neisseria meningitidis serogroup A, measles, Streptococcus pneumoniae, rotavirus, rubella, and yellow fever.

The World Health Assembly, with the support of various countries and partners, launched a strategy called the Immunization Agenda 2030 in 2020. This initiative aims to address vaccination challenges and save over 50 million lives by 2030. In the US, vaccination initiatives are diverse and include federal programs like the Vaccines for Children program, as well as state and local efforts and partnerships with various organizations. As the programs aim to increase vaccination rates, ensure equitable access to vaccines, and combat diseases that can be prevented through vaccination, the vaccines market continues to grow at a significant rate.

Development of Combination and Therapeutic Vaccines to Create Growth Opportunities

The vaccine industry is currently experiencing a transformative phase, with combination and therapeutic vaccines emerging as the most promising opportunities for manufacturers. Innovations in these vaccines not only address evolving public health challenges but also provide significant commercial and operational advantages.

Combination vaccines are formulations designed to protect against multiple diseases in a single shot. Traditionally used in pediatric care, as seen with vaccines like MMR (measles, mumps, rubella) and DTP (diphtheria, tetanus, pertussis), combination vaccines are now expanding their reach to adult and elderly populations. This is particularly relevant for respiratory illnesses such as influenza, COVID-19, and Respiratory Syncytial Virus (RSV). Combination vaccines can greatly improve immunization rates, resulting in a quicker and more extensive reduction in disease burden. They are especially important as new vaccines for diseases such as dengue, typhoid, RSV, and tuberculosis are being developed. According to Gavi, by 2030, combination vaccines will provide protection against 30 infections with fewer doses.

Major pharmaceutical companies, including Moderna, Pfizer/BioNTech, Novavax, Sanofi, GSK, and AstraZeneca, are developing combination vaccines for COVID-19, influenza, and RSV. These products are anticipated to transform seasonal immunization strategies and enhance uptake among adults and elderly populations. In June 2025, Moderna, Inc. announced that the US Food and Drug Administration (FDA) approved mRESVIA (mRNA-1345), the company's RSV vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals aged 18–59 years who are at increased risk for disease. This approval expanded the previous indication of mRESVIA, which was approved in May 2024 for adults aged 60 years and older.

Additionally, therapeutic vaccines are designed not to prevent diseases but to treat existing conditions, which can include chronic infections, cancers, and allergies. This approach represents a new frontier in vaccine technology, utilizing advancements in mRNA, viral vectors, and personalized medicine. For instance, cancer vaccines aim to stimulate the immune system to recognize and attack tumor cells. Additionally, some vaccines are being developed for chronic infections such as hepatitis B and HIV. As of 2024, the US Food and Drug Administration (FDA) has approved three therapeutic vaccines: Sipuleucel-T for advanced prostate cancer, Bacillus Calmette-Guérin for high-risk, non-muscle-invasive bladder cancer, and Talimogene laherparepvec for melanoma. Therefore, the development of combination and therapeutic vaccines presents substantial opportunities for vaccine manufacturers to grow, innovate, and create a meaningful impact. These vaccines simplify immunization, expand their applications, and address both preventive and therapeutic health needs worldwide.

Vaccines Market Report Segmentation Analysis

Key segments that are the foundation of vaccines market analysis are type, indication, route of administration, and age group.

  • Based on type, the vaccines market is segmented into conjugated vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. The conjugated vaccines segment held the largest share of the market in 2024.
  • In terms of indication, the vaccines market is categorized into HPV, PCV, DTP, hepatitis, influenza, dengue, and others. The HPV segment dominated the market in 2024.
  • By route of administration, the market is classified into injection, oral, and other. The injection segment dominated the vaccines market share in 2024.
  • In terms of age group, the vaccines market is bifurcated into pediatric and adult. The pediatric segment dominated the market in 2024.

Vaccines Market Share Analysis by Geography

The geographical scope of the vaccines market report is divided into five regions: North America, Asia Pacific, Europe, the Middle East and Africa, and South and Central America.

North America held a significant share of the market in 2024. A primary catalyst is the increase in cases of infectious diseases, which has created sustained demand for preventive healthcare solutions, including vaccines. Mass immunization programs for the prevention of infectious diseases drive the need for vaccines on a large scale, owing to which several initiatives and strategies are being encouraged to enhance vaccine production facilities in North America. Moreover, private sector partnerships, international collaborations, and increased funding from both government and non-government organizations have fueled the pipeline for new vaccine candidates. Rising awareness about travel-related vaccinations and the resurgence of preventable diseases such as measles due to vaccine hesitancy have also spotlighted the importance of immunization, thereby stimulating market growth.

Vaccines Market Regional Insights

The regional trends and factors influencing the Vaccines Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Vaccines Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

vaccines-market-global-geography
  • Get the Regional Specific Data for Vaccines Market

Vaccines Market Report Scope

Report Attribute Details
Market size in 2024 US$ 80.45 Billion
Market Size by 2031 US$ 118.94 Billion
Global CAGR (2025 - 2031) 5.7%
Historical Data 2021-2023
Forecast period 2025-2031
Segments Covered By Type
  • Conjugated Vaccines
  • Inactivated and Subunit Vaccines
  • Live Attenuated Vaccines
  • Recombinant Vaccines
  • Toxoid Vaccines
By Indication
  • HPV
  • PCV
  • DTP
  • Hepatitis
  • Influenza
  • Dengue
  • Others
By Route of Administration
  • Injection
  • Oral
  • Other
By Age Group
  • Pediatric
  • Adult
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • GlaxoSmithKline plc
  • Sanofi SA
  • CSL Seqirus
  • Abbott
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd
  • Pfizer Inc.
  • Mylan NV
  • Novartis
  • Merck

  • Vaccines Market Players Density: Understanding Its Impact on Business Dynamics

    The Vaccines Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

    Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

    Major Companies operating in the Vaccines Market are:

    1. GlaxoSmithKline plc
    2. Sanofi SA
    3. CSL Seqirus
    4. Abbott
    5. Serum Institute of India Pvt. Ltd.
    6. Sinovac Biotech Ltd

    Disclaimer: The companies listed above are not ranked in any particular order.


    vaccines-market-cagr

    • Get the Vaccines Market top key players overview

    Vaccines Market News and Recent Developments

    The vaccines market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A key development in the market is listed below:

    • Serum Institute of India, the world’s largest vaccine manufacturer by dose volume, entered into an exclusive global agreement with ImmunityBio, Inc., to supply Bacillus Calmette-Guerin (BCG) to ImmunityBio. The deal includes the production of standard BCG, approved for use outside the US, as well as a next-generation recombinant BCG (iBCG), currently undergoing testing. The two companies collaborate to expedite the Phase 2 clinical trials of iBCG being conducted in Europe. (Source: Serum Institute of India Pvt. Ltd., Press Release, May 2024)
    • GSK entered into an agreement with the Government of Canada for pandemic and seasonal influenza vaccines to help protect Canadian adults and children. The four-year agreement, spanning through March 2026, includes the supply of as many as 80 million doses of Arepanrix (adjuvanted pandemic influenza vaccine) in the event of an influenza pandemic(s) and a minimum of 4 million doses per year of Flulaval Tetra (seasonal influenza vaccine). (Source: GlaxoSmithKline plc., Press Release, July 2022)

    Vaccines Market Report Coverage and Deliverables

    The "Vaccines Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

    • Vaccines market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Vaccines market trends and market dynamics, such as drivers, restraints, and key opportunities
    • Detailed PEST and SWOT analysis
    • Vaccines market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments in the vaccines market
    • Detailed company profiles

    Frequently Asked Questions

    Which region dominated the vaccines market in 2024?

    North America dominated the market in 2024.

    What are the factors driving vaccines market growth?

    The growing incidences of infectious diseases and disease outbreaks, and surging immunization programs and government initiatives contribute to market growth.

    Which are the leading players operating in the vaccines market?

    GlaxoSmithKline plc, Sanofi SA, CSL Seqirus, Abbott, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd, Pfizer Inc., Mylan NV, Novartis, and Merck are among the key players operating in the vaccines market.

    What is the estimated value of the vaccines market by 2031?

    The market is expected to reach US$ 118.94 billion by 2031.

    What is the expected CAGR of the vaccines market?

    The market is estimated to register a CAGR of 5.7% during the forecast period.

    Mrinal Kerhalkar
    Mrinal Kerhalkar
    Manager,
    Market Research & Consulting

    Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

    Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset

    Testimonials

    user

    I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.

    DR CHIJIOKE ONYIA, MANAGING DIRECTOR, PineCrest Healthcare Ltd.
    user

    The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services

    Yukihiko Adachi CEO, Deep Blue, LLC.

    Reason to Buy

    • Informed Decision-Making
    • Understanding Market Dynamics
    • Competitive Analysis
    • Customer Insights
    • Market Forecasts
    • Risk Mitigation
    • Strategic Planning
    • Investment Justification
    • Identifying Emerging Markets
    • Enhancing Marketing Strategies
    • Boosting Operational Efficiency
    • Tracking Industry Innovations
    • Aligning with Regulatory Trends
    Your Key Concerns Addressed - Question & Answer
    Can I view a sample of the report before purchasing?

    Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.

    Is analyst support included with the purchase?

    Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.

    What are the next steps once I place an order?

    Once your order is successfully placed, you will receive a confirmation email along with your invoice.

    • For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
    • For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.

    Can the report be tailored to suit my specific needs?

    We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.

    In what format is the report delivered?

    The report is available in either PDF format or as an Excel dataset, depending on the license you choose.

    The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
    Please review the license options at checkout or contact us to confirm which formats are included with your purchase.

    How secure is the payment process on your platform?

    Our payment process is fully secure and PCI-DSS compliant.

    We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
    You can make your purchase with confidence, knowing your personal and financial information is safe with us.

    Do you provide special pricing for buying multiple reports?

    Yes, we do offer special pricing for bulk purchases.
    If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.

    Can I connect with your team to discuss the report before buying?

    Yes, absolutely.
    Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.

    Will I get a billing invoice upon purchase?

    Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
    If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.

    Is there support available if I can’t access my report?

    Yes, certainly.
    If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.

    Our Clients

    The List of Companies - Vaccines Market

    • GlaxoSmithKline plc
    • Sanofi SA
    • CSL Seqirus
    • Abbott
    • Serum Institute of India Pvt. Ltd.
    • Sinovac Biotech Ltd
    • Pfizer Inc
    • Mylan NV
    • Novartis
    • Merck
    Sales Assistance
    US: +1-646-491-9876
    UK: +44-20-8125-4005
    Email: sales@theinsightpartners.com
    Chat with us
    DUNS Logo
    87-673-9708
    ISO Certified Logo
    ISO 9001:2015
    ISO Certified Logo